ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$23.64 USD
-0.40 (-1.66%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $23.64 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACAD 23.64 -0.40(-1.66%)
Will ACAD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACAD
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Other News for ACAD
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference | ...
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer | ACAD Stock News
10 Health Care Stocks Whale Activity In Today's Session
Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In
JP Morgan Raises Price Target for ACADIA Pharmaceuticals (ACAD) | ACAD Stock News